While Rhythm Pharmaceuticals Inc has overperformed by 1.03%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RYTM rose by 57.43%, with highs and lows ranging from $68.58 to $35.17, whereas the simple moving average jumped by 12.10% in the last 200 days.
On April 07, 2025, BofA Securities Upgraded Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) to Buy. Jefferies also rated RYTM shares as ‘Buy’, setting a target price of $80 on the company’s shares in an initiating report dated January 02, 2025. Oppenheimer Initiated an Outperform rating on December 20, 2024, and assigned a price target of $76. Guggenheim initiated its ‘Buy’ rating for RYTM, as published in its report on October 21, 2024. H.C. Wainwright’s report from September 18, 2024 suggests a price prediction of $64 for RYTM shares, giving the stock a ‘Buy’ rating. JMP Securities also rated the stock as ‘Mkt Outperform’.
Analysis of Rhythm Pharmaceuticals Inc (RYTM)
Further, the quarter-over-quarter increase in sales is 72.61%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Rhythm Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -272.15% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.08, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and RYTM is recording an average volume of 642.09K. On a monthly basis, the volatility of the stock is set at 6.96%, whereas on a weekly basis, it is put at 4.06%, with a loss of -3.62% over the past seven days. Furthermore, long-term investors anticipate a median target price of $79.25, showing growth from the present price of $59.84, which can serve as yet another indication of whether RYTM is worth investing in or should be passed over.
How Do You Analyze Rhythm Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.97%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 95.16% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RYTM shares are owned by institutional investors to the tune of 95.16% at present.
